Compare Ascendis Pharma A/S (ASND) vs Enbridge Inc (ENB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Enbridge Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Enbridge Inc trades at $54.82 (market cap $118.96B). The key difference: Enbridge Inc is far larger — about 6.7× Ascendis Pharma A/S's market cap, and Enbridge Inc pays a 5.14% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ENB | |
|---|---|---|
Market Cap | $17.74B | $118.96B |
Sector | Health | Energy |
52-Week High | $277.18 | $58.04 |
52-Week Low | $163.32 | $44.55 |
Enterprise Value | $18.11B | $199.76B |
Dividend Yield | — | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Enbridge (ENB) trades at $54.66, up 0.13% on the day, with a neutral technical signal and mixed earnings history. The company reported strong revenue growth to $65.19B in 2025 and maintains a 10% net income margin. Recent news highlights its 5.1% dividend yield and AI-driven growth projects, while analyst consensus is evenly split between Buy and Hold ratings.
Outlook remains balanced with steady cash flow and dividend appeal offset by high debt levels and earnings volatility. Key opportunities include infrastructure expansion and high yield, while risks involve interest rate sensitivity and execution challenges in capital projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
